What if you invested $1000 in OGN on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 5 years, Organon & Co. has delivered an average annual return of -20.5%. The stock peaked in 2024 with a massive +7.7% gain, while investors faced a downturn in 2025 (-51.0%). Overall, the stock finished in the green 1 times out of 5 years.
Avg Return
-20.5%
Win Rate
20%
1W - 4L
Best
+7.7%
2024
Worst
-51.0%
2025
Performance Consistency
About Organon & Co.
Visit Website ↗Organon is a global healthcare company formed through a spin-off from Merck. It focuses on improving the health of women throughout their lives.
Key Business Segments
Women's Health
Contraception (Nexplanon) and fertility.
Biosimilars
Oncology and immunology biosimilars.
Established Brands
Respiratory, cardiovascular, and dermatology medicines.
Key Innovations
- ✓Focus on unmet women's health needs
Historical Milestones
Original Organon founded in the Netherlands.
Spun off from Merck as an independent public company.